A 36 week randomized, double-blind, parallel group, multi-center, active-controlled, optional titration study comparing an aliskiren-based regimen to a ramipril-based regimen in patients greater than or equal to 65 years old with systolic essential hypertension.

Trial Profile

A 36 week randomized, double-blind, parallel group, multi-center, active-controlled, optional titration study comparing an aliskiren-based regimen to a ramipril-based regimen in patients greater than or equal to 65 years old with systolic essential hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2011

At a glance

  • Drugs Aliskiren; Ramipril
  • Indications Hypertension; Isolated systolic hypertension
  • Focus Therapeutic Use
  • Acronyms AGELESS
  • Sponsors Novartis
  • Most Recent Events

    • 24 Dec 2009 Resuts published in the Journal of Human Hypertension.
    • 21 Jul 2009 Actual end date (1 Feb 2008) added as reported by ClinicalTrials.gov.
    • 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top